Consensus WELL Health Technologies Corp.

Equities

WELL

CA94947L1022

Market Closed - Toronto S.E. 04:00:00 2024-06-12 pm EDT 5-day change 1st Jan Change
4.26 CAD +1.67% Intraday chart for WELL Health Technologies Corp. +11.23% +10.65%

Evolution of the average Target Price on WELL Health Technologies Corp.

Price target over the last 5 years

History of analyst recommendation changes

4dcbd9161d7ab6ca54f3bf6.Vm81u0pOcOnqlpLxnIxemmAanfItEcoswsC5gbtRWRE.BCh98mc0Ntq9_-KQyvwY0z9O5cBFUJ9auoXcxdoaI0EYX1rkPTgCoIT84Q~c919826bee518934a5fe7a925b3350eb
WELL Health Agrees to Automatic Share Purchase Plan with Broker MT
WELL Health Maintained at Buy at Stifel GMP as it Buys 10 Clinics From Shoppers Drug Mart; Price Target Kept at C$11.00 MT
WELL Health Technologies Rises 3%, TD Says Shopper Drug Mart Deal Likely For "Low Price" MT
WELL Health Technologies Initiated at Outperform, $5.50 Price Target at RBC MT
Well Health Brief: Says Achieved record quarterly revenues of $204.5 million; Raises Guidance for Balance of 2023 and Provides Guidance of Over $900 Million in Revenue for 2024 MT
WELL Health Technologies Maintained at Buy at Stifel GMP Following Clinic Acquisitions; Price Target Kept at C$13.50 MT
WELL Health Technologies Initiated at Outperform, $8.50 Price Target at Raymond James MT
WELL Health Technologies Buy Rating Reiterated at Stifel GMP Following Good Q4 Results; Price Target Kept at C$13.50 MT
WELL Health Reports Record Revenue and Adjusted EBITDA Results for Q3-2022 and Raises Guidance for Fourth Straight Quarter PR
WELL Health Technologies : Reports Record Revenue and Adjusted EBITDA Results for Q3-2022 and Raises Guidance for Fourth Straight Quarter PU
WELL Health Reports Record Quarterly Revenue and Adjusted EBITDA in Q2-2022 and Raises Guidance for 3rd Straight Quarter AQ
WELL Health Technologies Buy Rating Kept at Stifel GMP as Credit Facility Expanded MT
WELL Health Technologies Kept at Buy at Stifel GMP Following Formation of a Canadian Clinic Unit MT
Scotiabank's Take on Well Health's INLIV Acquisition MT
Scotiabank Maintains Outperform, $9 TP on Well Health After Company Releases Prelim Q1 Results MT
GUIDANCE: (WELL.TO) WELL HEALTH TECHNOLOGIES Adds This "Catapults" Its Estimated Proforma Annualized Revs Run Rate to Almost $400 Million with Adjusted EBITDA Run Rate Approaching $100 Million MT
Well Health Brief: In initiating Coverage, Scotia Analyst Adam Buckham Set a TP of $10.00/share and a 25.2% Rate of Return on Shares Within Next 12 Months, While Opening with a Sector Perform Rating, Cantech has noted MT
Well Health Brief: Scotiabank Has Sector Perform and $10 Price Target on It Vs Mostly Buy Ratings and Average PT on Bay Street of More Than $11.50, notes BNN TV MT
WELL HEALTH TECHNOLOGIES : Target Price Increased to $11 at TD, Analyst Sees More Acquisitions MT
WELL HEALTH TECHNOLOGIES : Rises More than 5%, TD Says MyHealth Acquisition Likely To Be Viewed "Positively" MT
WELL HEALTH TECHNOLOGIES : Upgraded to Buy After Intrahealth Acquisition MT
Well Health Brief: Cut To Hold With Target Price of $10.50 at Desjardins On Run Up In Shares (+12%) Following CRH Deal, says BNN Bloomberg TV MT
Well Health CRH Medical Corporation Webcast Brief: CEO Shahbazi Says CIBC and HSBC Debt Facility Rates Are Between 1.5% and 3.25% MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
4.19 CAD
Average target price
7.45 CAD
Spread / Average Target
+77.80%
High Price Target
10 CAD
Spread / Highest target
+138.66%
Low Price Target
4.75 CAD
Spread / Lowest Target
+13.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering WELL Health Technologies Corp.

Stifel GMP
TD Securities
RBC Capital Markets
Raymond James
Scotiabank
Desjardins
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock Market
  2. Equities
  3. WELL Stock
  4. Consensus WELL Health Technologies Corp.